Jim Lee

Jim Lee

Company: Incyte

Job title: Head Immunology & Inflammation


The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis 10:15 am

The story from discovery to clinical development for a moderate to severe inflammatory skin indication Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio Reviewing the commercialization and market strategy of a ‘twice daily’ applied topical creamRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.